Critically appraise the diagnosis and management of early-onset pre-eclampsia with severe features

In one line

Early-onset pre-eclampsia with severe features (severe features before 34 weeks) is a maternal multi-organ disease whose only cure is delivery — the whole craft is buying fetal maturity by expectant management while controlling blood pressure, giving magnesium sulphate for seizure prophylaxis, and recognising the precise moment when maternal or fetal deterioration makes continuing the pregnancy more dangerous than prematurity.

This chapter assumes the diagnostic groundwork in pre-eclampsia & HELLP basics and hypertension in pregnancy; it spends its words on the appraisal and the judgement calls. Prevention is covered in pre-eclampsia-prevention-aspirin and the drug-by-drug argument in hypertension-in-pregnancy-antihypertensives.

Why this matters in South Africa

Hypertensive disorders are consistently among the top causes of maternal death in the Saving Mothers reports, and the deaths cluster around two avoidable end-points: intracranial haemorrhage from uncontrolled severe hypertension, and pulmonary oedema from iatrogenic fluid overload. Both are failures of the early, cheap, protocol-driven steps — not of heroic tertiary care. Early-onset disease additionally collides with the SA reality that neonatal intensive care is scarce and unevenly distributed, so the "buy time" calculus that a high-income unit takes for granted is, in a district hospital, often a "stabilise and transfer" decision instead. Both the protocol that prevents the death and the system-level call about where the woman should be have to be right.

Pathophysiology — why early-onset disease behaves differently

Pre-eclampsia is best understood as a two-stage placental disease, and the early-onset phenotype is the one that maps most cleanly onto that model.

Stage 1 — defective spiral-artery remodelling. In normal pregnancy, extravillous trophoblast invades and converts the maternal spiral arteries into wide, low-resistance, high-flow conduits. In pre-eclampsia this conversion is incomplete: the arteries stay narrow and muscular, giving a placenta that is chronically under-perfused and subject to ischaemia–reperfusion injury. Early-onset disease is the placental phenotype — poor placentation dominates, which is exactly why it travels with fetal growth restriction and abnormal umbilical-artery Dopplers. (Late-onset disease, by contrast, is more often a maternal-constitutional phenotype with a relatively normal placenta.)
Stage 2 — the maternal syndrome. The ischaemic placenta releases anti-angiogenic factors into the maternal circulation: soluble fms-like tyrosine kinase-1 (sFlt-1), which scavenges circulating VEGF and placental growth factor (PlGF), and soluble endoglin (sEng). The result is widespread endothelial dysfunction — the unifying lesion that explains every organ manifestation: vasoconstriction (hypertension), increased vascular permeability (oedema, proteinuria, pulmonary oedema), a procoagulant endothelium (microangiopathy, HELLP), and impaired autoregulation in the cerebral circulation (eclampsia, posterior reversible encephalopathy). This is why the sFlt-1/PlGF ratio is biologically meaningful and not just a number — it indexes the driver of the maternal syndrome.

The practical corollaries follow from mechanism: the disease is multi-system (so investigate every organ, not just the BP), it is progressive and unpredictable (so a normal set of bloods now does not exclude HELLP in six hours), and it is only cured by removing the placenta (so every management plan ends, sooner or later, in delivery).

Assessment

The diagnosis is not the difficulty — defining the severe phenotype and tracking its trajectory is. Severe features (ACOG 2020) are: BP ≥160/110 on two occasions ≥4 h apart (or once if treatment is started sooner); platelets <100 × 10⁹/L; transaminases >2× upper limit of normal or severe RUQ/epigastric pain; creatinine >1.1 mg/dL (≈97 µmol/L) or doubling; pulmonary oedema; or new cerebral/visual symptoms. Proteinuria quantity is not a severity marker and is not needed to diagnose pre-eclampsia once organ involvement is present.

History — the symptoms that signal end-organ involvement, not just "feeling unwell":

Headache unresponsive to simple analgesia — cerebral vasogenic oedema; the herald of eclampsia.
Visual disturbance — scintillations, scotomata, blurring or transient cortical blindness (occipital oedema/PRES).
Epigastric or right-upper-quadrant pain — stretching of the hepatic (Glisson's) capsule from periportal haemorrhage/oedema; the symptom of HELLP and a warning of subcapsular haematoma.
Breathlessness or orthopnoea — pulmonary oedema, the second great killer.
Reduced fetal movements — placental insufficiency.
Anchor the gestation precisely: every subsequent decision pivots on it.

Examination — organ by organ:

Cardiovascular — confirmed severe BP (correct cuff size, seated, arm at heart level), and signs of overload (raised JVP, gallop).
Respiratory — respiratory rate (>24 is an early sign of pulmonary oedema), oxygen saturation, basal crepitations.
Neurological — hyperreflexia and sustained clonus (>3 beats) signal cortical irritability and heighten eclampsia risk; assess conscious level.
Abdominal — RUQ/epigastric tenderness; symphysis–fundal height against the growth chart.
Fetal — CTG if viable, and a clinical estimate of liquor and presentation.

Investigations and what each is for:

FBC + smear — thrombocytopenia (consumption), and a haemolytic film (schistocytes, fragments) for HELLP. A falling platelet trend matters more than a single value.
U&E / creatinine — acute kidney injury from renal hypoperfusion/glomerular endotheliosis; oliguria.
ALT/AST and LDH — transaminitis and haemolysis. The HELLP trajectory is rising LDH and transaminases with falling platelets; repeat 6–12-hourly, because a single normal set does not exclude evolving disease.
Coagulation (PT/aPTT/fibrinogen) — only if platelets are very low, there is bleeding, or abruption/DIC is suspected; fibrinogen <2 g/L in this setting is ominous.
Uric acid — rises with disease but is a weak, non-diagnostic marker; do not hang management on it.
Fetus — dating (or EFW if undated), umbilical-artery Doppler, and serial growth. Early-onset disease is the placental phenotype, so FGR and absent or reversed end-diastolic flow are common and shift the delivery calculus; a ductus venosus assessment helps time delivery at the extremes of viability.

Think about the differential of microangiopathy, because the management diverges: HELLP (the common one), acute fatty liver of pregnancy (hypoglycaemia, marked coagulopathy, raised ammonia/bilirubin), and the thrombotic microangiopathies TTP and atypical HUS (more haemolysis and renal failure, less hepatic and BP derangement, and crucially do not resolve with delivery — they need plasma exchange or complement blockade). Getting this wrong delays the right treatment.

Risk stratification. The fullPIERS model predicts adverse maternal outcome within 48 h of admission (development AUC 0.88) and is a defensible tool to triage transfer and counselling, though it informs rather than dictates. Angiogenic markers (sFlt-1/PlGF): a ratio ≤38 has a ~99.3% negative predictive value for developing pre-eclampsia within one week (PROGNOSIS), so the marker is strongest at ruling out in suspected — not established — disease; its role once severe features exist is prognostic, not diagnostic. Revealing the PlGF result in suspected disease also speeds diagnosis (median 4.1→1.9 days) and reduces severe maternal outcomes (PARROT).

Management

Work immediate → ongoing → long-term.

Immediate (stabilise the mother, then decide on the fetus).

Problem	SA first line (NDoH)	International (NICE NG133 / ACOG)
Acute severe BP ≥160/110	Nifedipine 10 mg PO (swallowed, not sublingual); repeat after 30 min; if still severe after three doses, IV labetalol 20 mg then 40 mg	Oral nifedipine, IV labetalol, or IV hydralazine — treat within 30–60 min
Seizure prophylaxis / eclampsia	MgSO₄ 4 g IV over ~20 min plus 5 g deep IM into each buttock (Pritchard, 14 g total), then 5 g IM 4-hourly; or 4 g in 200 mL at 50 mL/h if a pump is available	MgSO₄ 4 g IV over 5–15 min, then 1 g/h infusion for 24 h (Magpie/Zuspan)
Fluid	Restrict: 200 mL Ringer's bags at 80 mL/h	Limit maintenance fluids to 80 mL/h

A few points worth expanding on:

MgSO₄ is not an antihypertensive — lower BP with a rapid-acting agent first. Target BP roughly ≤150/100 acutely (avoid overshoot, which compromises placental perfusion); the maintenance target is ≤135/85 (NICE).
Antihypertensive choice and escalation. All three first-line agents — oral nifedipine, IV/oral labetalol, IV hydralazine — are acceptable; the right one is the one you can give safely and fast. Avoid labetalol in asthma and significant heart block; hydralazine can cause maternal tachycardia and a precipitous drop (preload with a small fluid bolus only if intravascularly deplete). If severe hypertension is refractory to escalating doses, that is itself an indication to deliver. The drug-by-drug argument and the postnatal switches are developed in hypertension-in-pregnancy-antihypertensives.
Magnesium monitoring and toxicity. Therapeutic range is roughly 2–3.5 mmol/L; toxicity is clinically monitored (levels are rarely needed). Track, hourly: patellar reflexes (lost first, at ~4–5 mmol/L), respiratory rate (depression at ~5–6.5 mmol/L; hold the infusion if <12–14/min), and urine output (magnesium is renally cleared, so oliguria → accumulation; reduce the maintenance dose if output <100 mL/4 h). Keep 10% calcium gluconate 10 mL IV drawn up as the antidote for respiratory compromise.
Fluid discipline. Capillary leak plus low oncotic pressure makes iatrogenic pulmonary oedema easy; cap total input at ~80 mL/h and resist the urge to "flush" oliguria — pre-eclamptic oliguria is usually a transient renal vasoconstriction that recovers after delivery, and aggressive loading drowns the lungs. A persistently rising creatinine or true anuria, not a single low hourly output, is what prompts escalation.
Steroids and neuroprotection. Give a course of antenatal corticosteroids (betamethasone or dexamethasone) if <34–36 weeks and birth is anticipated within 7 days, and antenatal MgSO₄ for fetal neuroprotection if delivery before ~32 weeks is likely (it doubles as the seizure-prophylaxis infusion the mother already needs).
Senior, multidisciplinary, HDU-level care. Early-onset severe disease belongs under consultant obstetric, anaesthetic and (where the fetus is viable) neonatal input, with strict fluid-balance charting and a documented escalation plan.

Ongoing — the expectant-management decision. Below 34 weeks, in a stable woman with controllable BP and reassuring fetal status, expectant management at a unit able to deliver and resuscitate is appropriate, with daily-or-more maternal review, BP control, serial bloods and fetal surveillance. Deliver regardless of gestation for any of:

uncontrollable severe hypertension despite maximal therapy;
eclampsia;
pulmonary oedema;
placental abruption;
DIC or rapidly falling platelets;
progressive renal or hepatic dysfunction, or a suspected hepatic subcapsular haematoma;
non-reassuring fetal status (repeated late decelerations, reversed ductus venosus a-wave, or a clearly failing biophysical picture);
a previable or extremely preterm fetus where continuing only adds maternal risk.

In SA the structural reality is decisive: district hospitals stabilise and transfer (MgSO₄ started, BP controlled, an escort continuing the regimen) to regional/tertiary care — expectant management of the very-preterm fetus belongs where neonatal ICU exists. Mode of delivery is an obstetric decision: vaginal birth is preferred and not contraindicated by pre-eclampsia per se, and the SA guideline explicitly favours it where the cervix is favourable and the fetal condition allows time; caesarean is chosen for the usual obstetric reasons (an unfavourable cervix at very early gestation, or a fetus that will not tolerate labour). Anaesthetic note: regional anaesthesia is generally preferred (it avoids the hypertensive surge of intubation and the airway risk of laryngeal oedema), but requires a platelet count that is safe and stable — many units use a threshold around >70–75 × 10⁹/L and a falling trend gives pause; general anaesthesia demands obtunding the pressor response at laryngoscopy.

Long-term. Continue MgSO₄ for 24 h post-delivery and antihypertensives until BP settles; the highest eclampsia and pulmonary-oedema risk is the first 24–48 h postpartum, so monitoring does not relax when the baby is out. Postnatal management, drug switches and counselling are in hypertension-in-pregnancy-antihypertensives; watch for postpartum haemorrhage compounded by thrombocytopenia (postpartum-haemorrhage) — and note that ergometrine is contraindicated because it raises BP. Counsel on ~1-in-5 recurrence (higher and earlier the earlier this episode was), lifelong cardiovascular risk (a roughly doubled long-term risk of chronic hypertension, ischaemic heart disease and stroke — pre-eclampsia is a cardiovascular risk marker, so hand the woman a primary-care follow-up plan), and aspirin from the first trimester for the next pregnancy.

The evidence & the controversy

The 34-week line is a convention, not a biological cliff. It rests on older RCTs and the Cochrane synthesis (Churchill 2018, 6 trials/748 women) showing expectant management before 34 weeks prolongs pregnancy (~10 days later birth) and reduces neonatal morbidity — fewer intraventricular haemorrhages (interventionist RR 1.94), less respiratory distress (RR 2.30) and less ventilation (RR 1.50) — but on low-to-very-low-quality evidence and with unproven maternal safety. Read alongside MEXPRE Latin, which found prolongation without a neonatal-mortality benefit and more abruption and SGA: expectant management is a trade-off, not a free lunch. ACOG and NICE both endorse expectant management <34 weeks in selected stable women, but only the right woman: tight BP control, normal-and-stable bloods, reassuring Dopplers, and a unit that can act within hours.

For late-preterm disease the pendulum has swung to delivery, and the LMIC evidence is now direct. In CRADLE-4 (India and Zambia, 34+0–36+6 weeks, n=565), planned delivery did not worsen the perinatal composite (adjusted risk difference −3.4%, 90% CI −8.7 to 1.9) and reduced stillbirth (RR 0.25, 95% CI 0.07–0.87) and severe maternal hypertension (aRR 0.83, 95% CI 0.70–0.99). This is the trial to cite for SA practice precisely because it was run in low-resource settings — its external validity to a Johannesburg regional hospital is far stronger than a UK trial's.

Two appraisal points matter most. First, magnesium: Magpie (n=10,141) more than halved eclampsia (RR 0.42, 95% CI 0.29–0.60 — 11 fewer eclamptic women per 1000) with a non-significant trend to lower maternal death (RR 0.55, 0.26–1.14) and less abruption (RR 0.67) — a cheap, EML-listed intervention that is one of obstetrics' clearest wins, and the reason every SA maternity facility must stock it. Second, blood-pressure targets: CHIPS settled that "less-tight" control (diastolic 100) offers no perinatal benefit over "tight" control (diastolic 85) and causes more severe hypertension (40.6% vs 27.5%) — so there is no fetal justification for permissive hypertension. Note CHIPS studied non-severe hypertension; it informs the maintenance target, not the acute severe emergency.

Where genuine uncertainty remains: the lower gestational bound for expectant management (offering it at 24–26 weeks trades a high maternal-risk pregnancy for very uncertain neonatal survival — an individualised, counselled decision that in SA must be honest about local neonatal outcomes), and the still-evolving role of angiogenic markers in managing (versus screening) established severe disease.

Landmark trials & key evidence

The expectant-vs-deliver evidence splits by gestational window, so each trial maps onto a particular woman.

Trial (year)	Question	Key finding	What it changed
Magpie (2002)	Does MgSO₄ prevent eclampsia in pre-eclampsia? (n=10,141, 33 countries)	Eclampsia RR 0.42 (95% CI 0.29–0.60) — ~58% relative reduction, 11 fewer eclamptic women per 1000; maternal death RR 0.55 (0.26–1.14); abruption RR 0.67	Made MgSO₄ the universal seizure-prophylaxis standard — cheap, EML-listed, mandatory stock in every SA maternity unit
Cochrane: interventionist vs expectant care, 24–34 wk (Churchill 2018)	Deliver promptly or expectantly manage severe PE before 34 wk? (6 trials, 748 women)	Interventionist care → more IVH (RR 1.94, 1.15–3.29), more RDS/hyaline membrane disease (RR 2.30, 1.39–3.81), more ventilation (RR 1.50, 1.11–2.02), ~10 days earlier birth; expectant care → more SGA	Underpins offering expectant management <34 wk in stable women — neonatal benefit, but low-quality evidence and unproven maternal safety
MEXPRE Latin (2013)	Does expectant management of severe PE at 28–33 wk improve neonatal outcome in limited-resource settings? (n=267)	Prolonged pregnancy 10.3 vs 2.2 days but no perinatal-mortality or neonatal-morbidity benefit; more abruption (RR 5.07, 1.13–22.7) and SGA (RR 2.27, 1.21–4.14)	The cautionary counterweight: expectant management buys days, not always better babies, and carries real maternal-fetal cost — individualise, don't default to it
CHIPS (2015)	"Less-tight" (dBP 100) vs "tight" (dBP 85) BP control in non-severe pregnancy hypertension? (n=987)	No difference in pregnancy loss/neonatal care or serious maternal complications, but severe hypertension 40.6% vs 27.5% (P<0.001) with less-tight control	Removed any fetal justification for permissive hypertension — sets the maintenance target at ≤135/85; note it studied non-severe disease
PHOENIX (2019)	Planned delivery vs expectant management for late-preterm PE, 34 to <37 wk? (UK, n=901)	Planned delivery reduced maternal morbidity (adjusted RR 0.86, 95% CI 0.79–0.94) at the cost of more neonatal-unit admission for prematurity (aRR 1.26, 1.08–1.47), without more neonatal morbidity	Shifted late-preterm practice toward planned delivery once 34 wk is reached
CRADLE-4 (2023)	Same question as PHOENIX but in LMICs (India + Zambia), 34–36 wk? (n=565)	Planned delivery non-inferior for the perinatal composite (adjusted risk difference −3.4%, 90% CI −8.7 to 1.9) and reduced stillbirth (RR 0.25, 0.07–0.87) and severe maternal hypertension (aRR 0.83, 0.70–0.99)	The externally valid trial for SA: confirms planned delivery from 34 wk is safe and stillbirth-sparing in low-resource settings
fullPIERS (2011)	Can a model predict adverse maternal outcome within 48 h of PE admission? (n=2,023)	Validated model (gestation, dyspnoea/chest pain, SpO₂, platelets, creatinine, AST) with AUC 0.88 (95% CI 0.84–0.92), holding up to 7 days	Gave a defensible bedside tool to triage transfer, level of care and counselling in early-onset disease
PROGNOSIS (Zeisler 2016)	Does the sFlt-1/PlGF ratio predict PE in suspected cases at 24–37 wk? (n=1,050)	Ratio ≤38 → 99.3% NPV (95% CI 97.9–99.9) for no pre-eclampsia within one week; ratio >38 PPV only 36.7% within 4 weeks	Positioned angiogenic markers as a powerful rule-out in suspected disease — not a diagnostic or management tool once severe features exist
PARROT (Duhig 2019)	Does revealing PlGF-based testing speed diagnosis and cut maternal harm in suspected pre-eclampsia? (stepped-wedge, 11 UK units)	Median time to PE diagnosis 4.1 → 1.9 days; severe maternal adverse outcomes 4% vs 5% (adjusted OR 0.32, 95% CI 0.11–0.96)	Made revealed PlGF testing standard in suspected disease — faster diagnosis, fewer severe maternal events
ACTOMgSO₄ (Crowther 2003)	Does antenatal MgSO₄ given for neuroprotection before birth <30 wk reduce death or cerebral palsy? (n=1,062, Australia/NZ)	Death-or-CP at 2 yr not significant (RR 0.83, 95% CI 0.66–1.03), but substantial gross motor dysfunction halved (3.4% vs 6.6%; RR 0.51, 0.29–0.91) and death-or-substantial-gross-motor-dysfunction RR 0.75 (0.59–0.96)	First RCT signalling antenatal magnesium neuroprotects the very-preterm brain — the rationale for giving MgSO₄ to the early-onset PE woman delivering very preterm
BEAM / MFMU (Rouse 2008)	Same question, 24–31 wk, placebo-controlled (n=2,241, US MFMU Network)	Primary composite (death or moderate/severe CP) not significant (RR 0.97, 95% CI 0.77–1.23), but moderate/severe CP among survivors reduced (1.9% vs 3.5%; RR 0.55, 0.32–0.95)	The pivotal trial behind universal antenatal MgSO₄ for fetal neuroprotection <32 wk — it conveniently doubles as the seizure-prophylaxis infusion the PE mother already needs

Worked viva — how to structure the answer

Examiners give a stem like "a 29-year-old, 30 weeks, BP 172/116, headache, platelets 88, ALT 140." A high-scoring answer runs:

Frame it — "This is early-onset pre-eclampsia with severe features with evolving HELLP at 30 weeks; she has two severe features and a symptom of cerebral irritability."
Resuscitate and make safe — acute BP control to ≤150/100, MgSO₄ loading, fluid restriction, senior + anaesthetic + neonatal alert, full bloods 6-hourly.
Decide the pregnancy — "I would stabilise and, given evolving HELLP and cerebral symptoms, I am leaning toward delivery rather than expectancy; I would give steroids and start the magnesium that also gives neuroprotection at this gestation, and deliver in a unit with neonatal ICU — transferring if I am not in one."
Justify from evidence — cite the expectant-vs-deliver split (Cochrane/MEXPRE below 34 weeks; the deterioration criteria that override expectancy), Magpie for magnesium, CHIPS for the target.
Anticipate complications — eclampsia, pulmonary oedema, abruption, PPH with low platelets, the postpartum window.
Close the loop — recurrence counselling, cardiovascular follow-up, aspirin next time.

Exam traps & red flags

Giving magnesium and thinking the BP is treated. MgSO₄ prevents seizures; it does not lower BP. Uncontrolled severe hypertension → cerebral haemorrhage, the leading cause of pre-eclampsia death in SA.
Sublingual nifedipine. The SA guideline is explicit: 10 mg swallowed, not sublingual/buccal — sublingual causes precipitous hypotension and fetal compromise.
Fluid loading a pre-eclamptic. Capillary leak plus low oncotic pressure means iatrogenic pulmonary oedema is easy; restrict to ~80 mL/h and watch a respiratory rate >24 as an early sign.
Chasing oliguria with fluids. Pre-eclamptic oliguria usually recovers after delivery; loading the circulation drowns the lungs. Treat the trend in creatinine, not a single low hourly output.
Forgetting the postpartum window. Eclampsia and pulmonary oedema frequently occur after delivery — continue MgSO₄ for 24 h and do not relax monitoring once the baby is out.
Anchoring on proteinuria for severity — heavy proteinuria does not make disease "severe"; organ dysfunction does. Conversely, normal bloods now do not exclude evolving HELLP — re-test.
Missing the mimic. Microangiopathy that worsens after delivery, with disproportionate renal failure or coagulopathy, is TTP/aHUS or acute fatty liver — not HELLP — and needs a different treatment.
Expectant management in the wrong place. Below 34 weeks at a district hospital without neonatal ICU, the safe move is stabilise-and-transfer, not local expectant management.
Ergometrine for PPH in a pre-eclamptic — it raises BP; use oxytocin (and address the low platelets).
Magnesium toxicity — loss of patellar reflexes → respiratory depression; monitor reflexes, respiratory rate and urine output, and keep 10% calcium gluconate available as the antidote.

Evidence anchors